Timolol
- Generic Name
- Timolol
- Brand Names
- Azarga, Betimol, Combigan, Cosopt, Duotrav, Istalol, Timoptic, Xalacom
- Drug Type
- Small Molecule
- Chemical Formula
- C13H24N4O3S
- CAS Number
- 26839-75-8
- Unique Ingredient Identifier
- 5JKY92S7BR
- Background
Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.
- Indication
Ophthalmic timolol is indicated for the treatment of increased intraocular pressure in patients with ocular hypertension or open-angle glaucoma. The oral form of this drug is used to treat high blood pressure. In certain cases, timolol is used in the prevention of migraine headaches.
- Associated Conditions
- Increased Intra Ocular Pressure (IOP), Migraine, Ocular Hypertension, Open Angle Glaucoma (OAG)
- Associated Therapies
- -
Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas
- Conditions
- Infantile Hemangioma
- Interventions
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- The University of Texas Health Science Center, Houston
- Target Recruit Count
- 174
- Registration Number
- NCT05479123
- Locations
- 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States
Absorption and Safety of Topical Timolol to Treat Chronic Wounds
- First Posted Date
- 2021-05-26
- Last Posted Date
- 2021-05-27
- Lead Sponsor
- VA Northern California Health Care System
- Target Recruit Count
- 40
- Registration Number
- NCT04903366
- Locations
- 🇺🇸
VA Northern California Health Care System, Mather, California, United States
Interval Intraocular Pressure in Intravitreal Injection Study
- Conditions
- GlaucomaIntraocular Pressure
- Interventions
- First Posted Date
- 2021-04-30
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 64
- Registration Number
- NCT04868175
- Locations
- 🇭🇰
HKSDS Program, Hong Kong, Hong Kong
Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).
- Conditions
- Ocular HypertensionPrimary Open Angle Glaucoma
- Interventions
- Drug: QLS-101Drug: Timolol Maleate
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Qlaris Bio, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT04830397
- Locations
- 🇺🇸
Dixon Eye Care, Albany, Georgia, United States
A Randomized Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine
- First Posted Date
- 2019-02-11
- Last Posted Date
- 2019-07-02
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT03836664
- Locations
- 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study
- Conditions
- Glaucoma; DrugsNormal Tension GlaucomaPrimary Open-angle Glaucoma
- Interventions
- First Posted Date
- 2017-10-26
- Last Posted Date
- 2020-12-31
- Lead Sponsor
- Wills Eye
- Target Recruit Count
- 35
- Registration Number
- NCT03323164
- Locations
- 🇺🇸
Glaucoma Research Center - Wills Eye Hospital, Philadelphia, Pennsylvania, United States
Beta Adrenergic Antagonist for the Healing of Chronic DFU
- Conditions
- Chronic Diabetic Foot UlcersNon Healing WoundDiabetic Neuropathic Ulcers
- Interventions
- Drug: Non biologically active gelDrug: Timolol
- First Posted Date
- 2017-09-14
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 35
- Registration Number
- NCT03282981
- Locations
- 🇺🇸
VA Northern California Health Care System, Mather, CA, Sacramento, California, United States
Timolol for the Treatment of Acne and Rosacea
- First Posted Date
- 2016-05-17
- Last Posted Date
- 2021-11-11
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 8
- Registration Number
- NCT02774590
- Locations
- 🇺🇸
Johns Hopkins Dermatology Department, Baltimore, Maryland, United States
A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension
- Conditions
- Open-Angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2016-04-19
- Last Posted Date
- 2019-02-25
- Lead Sponsor
- ForSight Vision5, Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT02742649
- Locations
- 🇵🇦
Clinica de Ojos Orillac - Calvo, Panama City, Panama
Topical Timolol for Infantile Hemangioma in Early Proliferative Phase
- First Posted Date
- 2016-04-07
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Target Recruit Count
- 70
- Registration Number
- NCT02731287
- Locations
- 🇪🇸
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
🇪🇸Hospital Virgen del Rocío, Sevilla, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.